Inovio Pharmaceuticals Q2 2024 GAAP EPS $(1.19) Misses $(1.10) Estimate, Sales $100.762K Miss $121.500K Estimate
Author: Benzinga Newsdesk | August 08, 2024 04:38pm
Inovio Pharmaceuticals (NASDAQ:
INO) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(1.10) by 8.18 percent. The company reported quarterly sales of $100.762 thousand which missed the analyst consensus estimate of $121.500 thousand by 17.07 percent. This is a 55.41 percent decrease over sales of $225.971 thousand the same period last year.
Posted In: INO